{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T08:31:23Z","timestamp":1788337883689,"version":"build-2803163510"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>\n                    Chronic kidney disease (CKD), whose prevalence is rising substantially, has become a major global health challenge. In this study, we developed linagliptin-loaded chitosan nanoparticles (HCS-LGP NPs) for the treatment of renal fibrosis. The synthesized nanoparticles exhibited a uniform particle size of 178.8 \u00b1 4.4 nm and a zeta potential of \u221229.9 \u00b1 2.5 mV, along with acid-responsive drug release properties.\n                    <jats:italic>In vitro<\/jats:italic>\n                    , the HCS-LGP NPs showed efficient cellular uptake in TGF-\u03b21-induced HK-2 cells and significantly inhibited cell proliferation by downregulating the expression of TGF-\u03b21 and Collagen I.\n                    <jats:italic>In vivo<\/jats:italic>\n                    studies demonstrated effective renal accumulation of HCS-LGP NPs in rats with renal fibrosis. Treatment with HCS-LGP NPs significantly reduced serum creatinine, blood urea nitrogen, and the protein levels of TGF-\u03b21 and Collagen I. Notably, the administration of HCS-LGP NPs promoted marked recovery from renal injury and markedly reduced collagen fiber deposition in rats with renal fibrosis. Histopathological analysis confirmed excellent biocompatibility, with no observable damage to the heart, liver, spleen, or lungs. These findings indicate that HCS-LGP NPs hold great potential as a targeted therapy for renal fibrosis, offering enhanced efficacy and a favorable safety profile.\n                  <\/jats:p>","DOI":"10.3389\/fphar.2026.1773015","type":"journal-article","created":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T06:47:48Z","timestamp":1773902868000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Linagliptin loaded chitosan nanoparticles for the efficient therapy of renal fibrosis"],"prefix":"10.3389","volume":"17","author":[{"given":"Zhixiang","family":"Wu","sequence":"first","affiliation":[{"name":"Department of Pediatrics, The Third Xiangya Hospital, Central South University","place":["Changsha, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanjuan","family":"He","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, The Fourth Hospital of Changsha, Changsha Hospital of Hunan Normal University","place":["Changsha, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Deng","sequence":"additional","affiliation":[{"name":"Hunan Normal University School of Medicine","place":["Changsha, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Tan","sequence":"additional","affiliation":[{"name":"Hunan Normal University School of Medicine","place":["Changsha, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wangzi","family":"Gao","sequence":"additional","affiliation":[{"name":"Hunan Normal University School of Medicine","place":["Changsha, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxin","family":"Yin","sequence":"additional","affiliation":[{"name":"Hunan Normal University School of Medicine","place":["Changsha, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziqin","family":"Zeng","sequence":"additional","affiliation":[{"name":"Hunan Normal University School of Medicine","place":["Changsha, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, The Third Xiangya Hospital, Central South University","place":["Changsha, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijuan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, The Third Xiangya Hospital, Central South University","place":["Changsha, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, The Third Xiangya Hospital, Central South University","place":["Changsha, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shentang","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, The Third Xiangya Hospital, Central South University","place":["Changsha, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1159\/000341487","article-title":"DPP-4 inhibition on top of angiotensin receptor blockade offers a new therapeutic approach for diabetic nephropathy","volume":"36","author":"Alter","year":"2012","journal-title":"Kidney and Blood Pressure Research"},{"key":"B2","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N. Engl. Journal Medicine"},{"key":"B3","doi-asserted-by":"publisher","first-page":"822870","DOI":"10.3389\/fmed.2022.822870","article-title":"Experimental aristolochic acid nephropathy: a relevant model to study AKI-to-CKD transition","volume":"9","author":"Baudoux","year":"2022","journal-title":"Front. Medicine"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1001\/jama.2019.14745","article-title":"Chronic kidney disease diagnosis and management: a review","volume":"322","author":"Chen","year":"2019","journal-title":"Jama"},{"key":"B5","doi-asserted-by":"publisher","first-page":"672","DOI":"10.3390\/pharmaceutics12070672","article-title":"Food effects on oral drug absorption: application of physiologically-based pharmacokinetic modeling as a predictive tool","volume":"12","author":"Cheng","year":"2020","journal-title":"Pharmaceutics"},{"key":"B6","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.phrs.2017.12.001","article-title":"Exploring the effects of DPP-4 inhibitors on the kidney from the bench to clinical trials","volume":"129","author":"Coppolino","year":"2018","journal-title":"Pharmacol. Research"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2759","DOI":"10.1517\/14656566.2011.613825","article-title":"Linagliptin for the treatment of type 2 diabetes","volume":"12","author":"Del Prato","year":"2011","journal-title":"Expert Opinion Pharmacotherapy"},{"key":"B8","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1056\/NEJMoa2108269","article-title":"Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes","volume":"385","author":"Gerstein","year":"2021","journal-title":"N. Engl. Journal Medicine"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1016\/j.kint.2019.01.010","article-title":"Mechanisms of GLP-1 receptor-independent renoprotective effects of the dipeptidyl peptidase type 4 inhibitor linagliptin in GLP-1 receptor knockout mice with 5\/6 nephrectomy","volume":"95","author":"Hasan","year":"2019","journal-title":"Kidney International"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1016\/S0140-6736(19)30772-X","article-title":"Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial","volume":"393","author":"Heerspink","year":"2019","journal-title":"Lancet London, Engl."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N. Engl. Journal Medicine"},{"key":"B12","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1159\/000339028","article-title":"Renal and cardiac effects of DPP4 inhibitors--from preclinical development to clinical research","volume":"36","author":"Hocher","year":"2012","journal-title":"Kidney and Blood Pressure Research"},{"key":"B13","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1056\/NEJMoa053107","article-title":"Efficacy and safety of benazepril for advanced chronic renal insufficiency","volume":"354","author":"Hou","year":"2006","journal-title":"N. Engl. Journal Medicine"},{"key":"B14","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1001\/jamainternmed.2013.12700","article-title":"Renoprotective effect of renin-angiotensin-aldosterone system blockade in patients with predialysis advanced chronic kidney disease, hypertension, and anemia","volume":"174","author":"Hsu","year":"2014","journal-title":"JAMA Intern Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/s41392-023-01379-7","article-title":"Kidney fibrosis: from mechanisms to therapeutic medicines","volume":"8","author":"Huang","year":"2023","journal-title":"Signal Transduction Targeted Therapy"},{"key":"B16","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1042\/CS20180031","article-title":"The role of renal dipeptidyl peptidase-4 in kidney disease: renal effects of dipeptidyl peptidase-4 inhibitors with a focus on linagliptin","volume":"132","author":"Kanasaki","year":"2018","journal-title":"Clin. Science Lond. Engl. 1979"},{"key":"B17","doi-asserted-by":"publisher","first-page":"3479","DOI":"10.1038\/s41598-023-30643-7","article-title":"The effect of linagliptin on microalbuminuria in patients with diabetic nephropathy: a randomized, double blinded clinical trial","volume":"13","author":"Karimifar","year":"2023","journal-title":"Sci. Reports"},{"key":"B18","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/s41581-019-0135-6","article-title":"Epigenetics and epigenomics in diabetic kidney disease and metabolic memory","volume":"15","author":"Kato","year":"2019","journal-title":"Nat. Reviews Nephrol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"e166643","DOI":"10.1172\/jci.insight.166643","article-title":"Tubular cell senescence promotes maladaptive kidney repair and chronic kidney disease after cisplatin nephrotoxicity","volume":"8","author":"Li","year":"2023","journal-title":"JCI Insight"},{"key":"B20","doi-asserted-by":"publisher","first-page":"e007525","DOI":"10.1136\/bmjgh-2021-007525","article-title":"Prevalence of chronic kidney disease in Asia: a systematic review and analysis","volume":"7","author":"Liyanage","year":"2022","journal-title":"BMJ Global Health"},{"key":"B21","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.pharmthera.2010.05.006","article-title":"Common pathophysiological mechanisms of chronic kidney disease: therapeutic perspectives","volume":"128","author":"L\u00f3pez-Novoa","year":"2010","journal-title":"Pharmacol. and Therapeutics"},{"key":"B22","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1056\/nejmoa1616011","article-title":"Liraglutide and renal outcomes in type 2 diabetes","volume":"377","author":"Mann","year":"2017","journal-title":"N. Engl. Journal Medicine"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1016\/j.mehy.2004.11.048","article-title":"Adjuvant strategies for prevention of glomerulosclerosis","volume":"67","author":"Mccarty","year":"2006","journal-title":"Med. Hypotheses"},{"key":"B24","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1093\/ndt\/gfw046","article-title":"End-stage renal disease in ANCA-Associated vasculitis","volume":"32","author":"Moiseev","year":"","journal-title":"Nephrol. Dialysis, Transplantation"},{"key":"B25","doi-asserted-by":"publisher","first-page":"e0160993","DOI":"10.1371\/journal.pone.0160993","article-title":"Linagliptin ameliorates methylglyoxal-induced peritoneal fibrosis in mice","volume":"11","author":"Nagai","year":"2016","journal-title":"PloS One"},{"key":"B26","doi-asserted-by":"publisher","first-page":"2827","DOI":"10.1152\/physrev.00027.2022","article-title":"Obstructivenephropathy and molecular pathophysiology of renal interstitial fibrosis","volume":"103","author":"N\u00f8rregaard","year":"2023","journal-title":"Physiol. Reviews"},{"key":"B27","doi-asserted-by":"publisher","first-page":"2579","DOI":"10.1007\/s00125-016-4083-4","article-title":"Effects of linagliptin on renal endothelial function in patients with type 2 diabetes: a randomised clinical trial","volume":"59","author":"Ott","year":"2016","journal-title":"Diabetologia"},{"key":"B28","doi-asserted-by":"publisher","first-page":"677","DOI":"10.2215\/CJN.07420716","article-title":"IgA nephropathy","volume":"12","author":"Rodrigues","year":"2017","journal-title":"Clin. Journal Am. Soc. Nephrol. CJASN"},{"key":"B29","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/s41581-019-0178-8","article-title":"Epidemiology, pathogenesis, treatment and outcomes of infection-associated glomerulonephritis","volume":"16","author":"Satoskar","year":"2020","journal-title":"Nat. Reviews Nephrol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1161\/CIRCRESAHA.117.311588","article-title":"Cardiovascular effects of new oral glucose-lowering agents: DPP-4 and SGLT-2 inhibitors","volume":"122","author":"Scheen","year":"2018","journal-title":"Circulation Research"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1038\/s41598-017-01888-w","article-title":"Physicochemical properties of dietary phytochemicals can predict their passive absorption in the human small intestine","volume":"7","author":"Selby-Pham","year":"2017","journal-title":"Sci. Reports"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1007\/s13346-020-00839-9","article-title":"Formulation development of linagliptin solid lipid nanoparticles for oral bioavailability enhancement: role of P-gp inhibition","volume":"11","author":"Shah","year":"2021","journal-title":"Drug Delivery Translational Research"},{"key":"B33","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1038\/ki.2014.298","article-title":"Nephrocalcinosis is a risk factor for kidney failure in primary hyperoxaluria","volume":"87","author":"Tang","year":"2015","journal-title":"Kidney Int."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1056\/NEJMoa1710030","article-title":"Tolvaptan in later-stage autosomal dominant polycystic kidney disease","volume":"377","author":"Torres","year":"2017","journal-title":"N. Engl. Journal Medicine"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1056\/NEJMc2207018","article-title":"Incidence of chronic kidney disease among adults with diabetes, 2015-2020","volume":"387","author":"Tuttle","year":"2022","journal-title":"N. Engl. Journal Medicine"},{"key":"B36","doi-asserted-by":"publisher","first-page":"2615","DOI":"10.1021\/jm020017n","article-title":"Molecular properties that influence the oral bioavailability of drug candidates","volume":"45","author":"Veber","year":"2002","journal-title":"J. Medicinal Chemistry"},{"key":"B37","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/S2213-8587(20)30369-7","article-title":"Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial","volume":"9","author":"Wheeler","year":"2021","journal-title":"Lancet Diabetes and Endocrinology"},{"key":"B38","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/ki.2015.175","article-title":"Evidence for antifibrotic incretin-independent effects of the DPP-4 inhibitor linagliptin","volume":"88","author":"Zeisberg","year":"2015","journal-title":"Kidney International"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1773015\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T06:47:49Z","timestamp":1773902869000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1773015\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,19]]},"references-count":38,"alternative-id":["10.3389\/fphar.2026.1773015"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1773015","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,19]]},"article-number":"1773015"}}